Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients

BMS-986001, a novel thymidine analog NRTI (nucleoside reverse transcriptase inhibitor) being developed by Oncolys BioPharma, when combined with efavirenz (Sustiva, Stocrin) and lamivudine (3TC, Epivir), was found to have comparable efficacy to tenofovir (Viread) in treatment-naive patients living with HIV, according to phase-2b study results presented by Samir K. Gupta, M.D., M.S., at ICAAC 2014 in Washington, D.C.

Published
10 September 2014
From
The Body
Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).

Published
10 September 2014
From
HIVand hepatitis.com
After two years on antiretroviral therapy, survival in South African patients meets rates from North America

Provided that therapy is started promptly, South Africans with HIV have chances of remaining alive beyond two years on antiretroviral therapy that are comparable to those of North American patients, according to new research.

Published
10 September 2014
From
Science Daily
Uganda: Aids Patients Reject Bitter ARVs

The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).

Published
10 September 2014
From
Allafrica.com
New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

Published
09 September 2014
From
HIVandhepatitis.com
Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

An analysis of people who experienced treatment failure on their first-line HIV therapy with a viral load of over 400 copies/ml and who had taken either

Published
09 September 2014
By
Gus Cairns
Social inequalities associated with late HIV diagnosis and delayed HIV treatment – European study

Even in the context of western European countries with universal access to health care, there are socioeconomic inequalities in timely access to HIV testing, according to a

Published
05 September 2014
By
Roger Pebody
EU marketing authorization for ViiV Healthcare HIV drug Triumeq

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

Published
04 September 2014
From
Pharma Letter
The Role of Triumeq in HIV Treatment

The approval of Triumeq, the single-tablet coformulation of abacavir, lamivudine and the integrase inhibitor dolutegravir, is an important step forward for antiretroviral therapy. Whereas all of the previously approved single-tablet regimens (STRs) contain tenofovir (Viread), which some people can't take, usually because of kidney disease, Triumeq does not contain tenofovir.

Published
04 September 2014
From
The Body
Malawi First Country to Put HIV Positive Pregnant Women On ARVs

President Arthur Peter Mutharika says Malawi was the first country to adopt a policy of putting all HIV positive pregnant and breast feeding women on anti-retroviral (ARV) drugs regardless of their CD4 Count.

Published
02 September 2014
From
AllAfrica

Filter by country